Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
To define the role of the human immunodeficiency virus type 1 (HIV-1) envelope proteins in virus infection, a series of peptides were synthesized based on various regions of the HIV-1 transmembrane protein gp41. One of these peptides, DP-178, corresponding to a region predictive of alpha-helical secondary structure (residues 643-678 of the HIV-1LAI isolate), has been identified as a potent antiviral agent. This peptide consistently blocked 100% of virus-mediated cell-cell fusion at < 5 ng/ml (IC90 approximately 1.5 ng/ml) and gave an approximately 10 times reduction in infectious titer of cell-free virus at approximately 80 ng/ml. The inhibitory activity was observed at peptide concentrations approximately 10(4) to 10(5) times lower than those at which cytotoxicity and cytostasis were detected. Peptide-mediated inhibition is HIV-1 specific in that approximately 10(2) to 10(3) times more peptide was required for inhibition of a human immunodeficiency virus type 2 isolate. Further experiments showed that DP-178 exhibited antiviral activity against both prototypic and primary HIV-1 isolates. As shown by PCR analysis of newly synthesized proviral DNA, DP-178 blocks an early step in the virus life cycle prior to reverse transcription. Finally, we discuss possible mechanisms by which DP-178 may exert its inhibitory activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus
Dalgleish, A. G., Beverley, P. C. L., Clapham, P. R., Crawford, D. H., Greaves, M. F., & Weiss, R. A. (1984) · Nature · doi:10.1038/312763a0 · Cited by 3,533
Spectroscopic Determination of Tryptophan and Tyrosine in Proteins*
Edelhoch, H. (1967) · Biochemistry · doi:10.1021/bi00859a010 · Cited by 3,436
Zack, J. A., Arrigo, S. J., Weitsman, S. R., Go, A. S., Haislip, A., & Chen, I. S. Y. (1990) · Cell · doi:10.1016/0092-8674(90)90802-l · Cited by 1,517
A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1
Muster, T., Steindl, F., Purtscher, M., Trkola, A., Klima, A., Himmler, G., Rüker, F., & Katinger, H. (1993) · Journal of Virology · doi:10.1128/jvi.67.11.6642-6647.1993 · Cited by 1,004
Human Retroviruses and Aids - 1999
Kuiken, C., & Foley, B. (1999) · doi:10.2172/1186019 · Cited by 952
Functional Regions of the Envelope Glycoprotein of Human Immunodeficiency Virus Type 1
Kowalski, M., Potz, J., Basiripour, L., Dorfman, T., Goh, W. C., Terwilliger, E., Dayton, A., Rosen, C., Haseltine, W., & Sodroski, J. (1987) · Science · doi:10.1126/science.3629244 · Cited by 848
Rusche, J. R., Javaherian, K., McDanal, C., Petro, J., Lynn, D. L., Grimaila, R., Langlois, A., Gallo, R. C., Arthur, L. O., & Fischinger, P. J. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.9.3198 · Cited by 620
Self-citationWild, C., Oas, T., McDanal, C., Bolognesi, D., & Matthews, T. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.21.10537 · Cited by 485
Self-citationA Synthetic Peptide from HIV-1 gp41 Is a Potent Inhibitor of Virus-Mediated Cell—Cell Fusion
Wild, C., Greenwell, T., & Matthews, T. (1993) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1993.9.1051 · Cited by 398
Self-citationA General Model for the Transmembrane Proteins of HIV and Other Retroviruses
GALLAHER, W. R., BALL, J. M., GARRY, R. F., GRIFFIN, M. C., & MONTELARO, R. C. (1989) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1989.5.431 · Cited by 368
Cited by
Core Structure of gp41 from the HIV Envelope Glycoprotein
Chan, D. C., Fass, D., Berger, J. M., & Kim, P. S. (1997) · Cell · doi:10.1016/s0092-8674(00)80205-6 · Cited by 1,959
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,661
Atomic structure of the ectodomain from HIV-1 gp41
Weissenhorn, W., Dessen, A., Harrison, S. C., Skehel, J. J., & Wiley, D. C. (1997) · Nature · doi:10.1038/387426a0 · Cited by 1,622
Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M., & Kappes, J. C. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1896-1905.2002 · Cited by 1,569
Bosch, B. J., van der Zee, R., de Haan, C. A. M., & Rottier, P. J. M. (2003) · Journal of Virology · doi:10.1128/jvi.77.16.8801-8811.2003 · Cited by 1,489
Synthetic therapeutic peptides: science and market
Vlieghe, P., Lisowski, V., Martinez, J., & Khrestchatisky, M. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2009.10.009 · Cited by 1,476
Mechanisms of Viral Membrane Fusion and Its Inhibition
Eckert, D. M., & Kim, P. S. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.777 · Cited by 1,282
Chan, D. C., & Kim, P. S. (1998) · Cell · doi:10.1016/s0092-8674(00)81430-0 · Cited by 1,277
Membrane Fusion and Exocytosis
Jahn, R., & Südhof, T. C. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.863 · Cited by 1,259
Harrison, S. C. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1456 · Cited by 1,190
Kilby, J. M., Hopkins, S., Venetta, T. M., DiMassimo, B., Cloud, G. A., Lee, J. Y., Alldredge, L., Hunter, E., Lambert, D., Bolognesi, D., et al. (1998) · Nature Medicine · doi:10.1038/3293 · Cited by 987
Self-citationHIV-1 Antiretroviral Drug Therapy
Arts, E. J., & Hazuda, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007161 · Cited by 851
Coronavirus membrane fusion mechanism offers a potential target for antiviral development
Tang, T., Bidon, M., Jaimes, J. A., Whittaker, G. R., & Daniel, S. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104792 · Cited by 761
Derdeyn, C. A., Decker, J. M., Sfakianos, J. N., Wu, X., O'Brien, W. A., Ratner, L., Kappes, J. C., Shaw, G. M., & Hunter, E. (2000) · Journal of Virology · doi:10.1128/jvi.74.18.8358-8367.2000 · Cited by 742
A trimeric structural domain of the HIV-1 transmembrane glycoprotein
Lu, M., Blacklow, S. C., & Kim, P. S. (1995) · Nature Structural & Molecular Biology · doi:10.1038/nsb1295-1075 · Cited by 701
Formyl-peptide receptors revisited
LE, Y., MURPHY, P., & WANG, J. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02316-5 · Cited by 597
Melikyan, G. B., Markosyan, R. M., Hemmati, H., Delmedico, M. K., Lambert, D. M., & Cohen, F. S. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.151.2.413 · Cited by 576
Hirsch, M. S., Günthard, H. F., Schapiro, J. M., Brun‐Vézinet, F., Clotet, B., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Mellors, J. W., Pillay, D., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/589297 · Cited by 573
VIRUS-CELL AND CELL-CELL FUSION
Hernandez, L. D., Hoffman, L. R., Wolfsberg, T. G., & White, J. M. (1996) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.12.1.627 · Cited by 567
Atomic structure of a thermostable subdomain of HIV-1 gp41
Tan, K., Liu, J.-H., Wang, J.-H., Shen, S., & Lu, M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12303 · Cited by 532
Liu, S., Xiao, G., Chen, Y., He, Y., Niu, J., Escalante, C. R., Xiong, H., Farmar, J., Debnath, A. K., Tien, P., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15788-7 · Cited by 505
A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike
Xia, S., Yan, L., Xu, W., Agrawal, A. S., Algaissi, A., Tseng, C.-T. K., Wang, Q., Du, L., Tan, W., Wilson, I. A., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav4580 · Cited by 501
Capture of an early fusion-active conformation of HIV-1 gp41
Furuta, R. A., Wild, C. T., Weng, Y., & Weiss, C. D. (1998) · Nature Structural Biology · doi:10.1038/nsb0498-276 · Cited by 488
Self-citationHIV-1 Envelope Glycoprotein Biosynthesis, Trafficking, and Incorporation
Checkley, M. A., Luttge, B. G., & Freed, E. O. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.04.042 · Cited by 479
Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target
Chan, D. C., Chutkowski, C. T., & Kim, P. S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15613 · Cited by 477
Chen, J., Lee, K. H., Steinhauer, D. A., Stevens, D. J., Skehel, J. J., & Wiley, D. C. (1998) · Cell · doi:10.1016/s0092-8674(00)81771-7 · Cited by 477
Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes
Matthews, T., Salgo, M., Greenberg, M., Chung, J., DeMasi, R., & Bolognesi, D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1331 · Cited by 465
Self-citationThe structural biology of type I viral membrane fusion
Colman, P. M., & Lawrence, M. C. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1076 · Cited by 454
The structural biology of HIV-1: mechanistic and therapeutic insights
Engelman, A., & Cherepanov, P. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2747 · Cited by 424
Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides
Rimsky, L. T., Shugars, D. C., & Matthews, T. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.986-993.1998 · Cited by 423
Self-citationSalzwedel, K., West, J. T., & Hunter, E. (1999) · Journal of Virology · doi:10.1128/jvi.73.3.2469-2480.1999 · Cited by 422
Bosch, B. J., Martina, B. E. E., van der Zee, R., Lepault, J., Haijema, B. J., Versluis, C., Heck, A. J. R., de Groot, R., Osterhaus, A. D. M. E., & Rottier, P. J. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400576101 · Cited by 416
Three-dimensional solution structure of the 44kDa ectodomain of SIV gp41
Caffrey, M. (1998) · The EMBO Journal · doi:10.1093/emboj/17.16.4572 · Cited by 410
He, Y., Zhou, Y., Liu, S., Kou, Z., Li, W., Farzan, M., & Jiang, S. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.09.106 · Cited by 403
Protein Design of an HIV-1 Entry Inhibitor
Root, M. J., Kay, M. S., & Kim, P. S. (2001) · Science · doi:10.1126/science.1057453 · Cited by 391
The HIV Env-mediated fusion reaction
Gallo, S. A., Finnegan, C. M., Viard, M., Raviv, Y., Dimitrov, A., Rawat, S. S., Puri, A., Durell, S., & Blumenthal, R. (2003) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(03)00161-5 · Cited by 391
Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor
Lu, L., Liu, Q., Zhu, Y., Chan, K.-H., Qin, L., Li, Y., Wang, Q., Chan, J. F.-W., Du, L., Yu, F., et al. (2014) · Nature Communications · doi:10.1038/ncomms4067 · Cited by 388
Structural basis for membrane fusion by enveloped viruses
Weissenhorn, Dessen, Calder, Harrison, Skehel, & Wiley, D. C. (1999) · Molecular Membrane Biology · doi:10.1080/096876899294706 · Cited by 372
Design and Creativity in Synthesis of Multivalent Neoglycoconjugates
Chabre, Y. M., & Roy, R. (2010) · Advances in Carbohydrate Chemistry and Biochemistry · doi:10.1016/s0065-2318(10)63006-5 · Cited by 319
Cohen, F. S., & Melikyan, G. B. (2004) · Journal of Membrane Biology · doi:10.1007/s00232-004-0669-8 · Cited by 319
Crystal Structure of HIV-1 gp41 Including Both Fusion Peptide and Membrane Proximal External Regions
Buzon, V., Natrajan, G., Schibli, D., Campelo, F., Kozlov, M. M., & Weissenhorn, W. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000880 · Cited by 285
Muñoz-Barroso, I., Durell, S., Sakaguchi, K., Appella, E., & Blumenthal, R. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.140.2.315 · Cited by 280
Zwick, M. B., Jensen, R., Church, S., Wang, M., Stiegler, G., Kunert, R., Katinger, H., & Burton, D. R. (2005) · Journal of Virology · doi:10.1128/jvi.79.2.1252-1261.2005 · Cited by 278
Yang, X., Lee, J., Mahony, E. M., Kwong, P. D., Wyatt, R., & Sodroski, J. (2002) · Journal of Virology · doi:10.1128/jvi.76.9.4634-4642.2002 · Cited by 277
Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region
Eckert, D. M., & Kim, P. S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201392898 · Cited by 271
Jiang, S., Lu, H., Liu, S., Zhao, Q., He, Y., & Debnath, A. K. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.11.4349-4359.2004 · Cited by 264
Kwong, P. D., Wyatt, R., Sattentau, Q. J., Sodroski, J., & Hendrickson, W. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.4.1961-1972.2000 · Cited by 263
Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-Å resolution
Malashkevich, V. N., Schneider, B. J., McNally, M. L., Milhollen, M. A., Pang, J. X., & Kim, P. S. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.2662 · Cited by 261
Resistance to enfuvirtide, the first HIV fusion inhibitor
Greenberg, M. L. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh330 · Cited by 258
McNeely, T. B., Shugars, D. C., Rosendahl, M., Tucker, C., Eisenberg, S. P., & Wahl, S. M. (1997) · Blood · doi:10.1182/blood.v90.3.1141 · Cited by 253
Self-citationMontero, M., van Houten, N. E., Wang, X., & Scott, J. K. (2008) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00020-07 · Cited by 253
Crystal Structure of Severe Acute Respiratory Syndrome Coronavirus Spike Protein Fusion Core
Xu, Y., Lou, Z., Liu, Y., Pang, H., Tien, P., Gao, G. F., & Rao, Z. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408782200 · Cited by 252
Role for Human Immunodeficiency Virus Type 1 Membrane Cholesterol in Viral Internalization
Guyader, M., Kiyokawa, E., Abrami, L., Turelli, P., & Trono, D. (2002) · Journal of Virology · doi:10.1128/jvi.76.20.10356-10364.2002 · Cited by 170
Metadata
- Authors
- Wild, C. T., Shugars, D. C., Greenwell, T. K., McDanal, C. B., & Matthews, T. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1994-10-11
- Volume
- 91
- Issue
- 21
- Pages
- 9770-9774
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2036656105
- Cited by
- 931
- References
- 24
- FWCI
- 4.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.